Survival advantage from imatinib compared with the combination interferon-α plus cytarabine in chronic-phase chronic myelogenous leukemia: Historical comparison between two phase 3 trials

Lydia Roy, Joëlle Guilhot, Tillmann Krahnke, Agnès Guerci-Bresler, Brian J. Druker, Richard A. Larson, Steve O'Brien, Charlene So, Giorgio Massimini, François Guilhot

Research output: Contribution to journalArticlepeer-review

190 Scopus citations

Fingerprint

Dive into the research topics of 'Survival advantage from imatinib compared with the combination interferon-α plus cytarabine in chronic-phase chronic myelogenous leukemia: Historical comparison between two phase 3 trials'. Together they form a unique fingerprint.

Medicine & Life Sciences

Chemical Compounds